Atsena Therapeutics Receives Rare Pediatric Disease Designation from FDA for ATSN-101 Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis (LCA1)

Positive 12-month safety and efficacy data from ongoing Phase I/II clinical trial of ATSN-101 to be presented at 47th Annual Macula Society Meeting on February 7, 2024 DURHAM, NC, January 16, 2024– Atsena Therapeutics, a clinical-stage...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials